These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
267 related items for PubMed ID: 34117815
1. CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer. Shiomi M, Matsuzaki S, Serada S, Matsuo K, Mizuta-Odani C, Jitsumori M, Nakae R, Matsuzaki S, Nakagawa S, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Ueda Y, Yoshino K, Naka T, Kimura T. Cancer Sci; 2021 Sep; 112(9):3655-3668. PubMed ID: 34117815 [Abstract] [Full Text] [Related]
9. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways. Shen W, Liang B, Yin J, Li X, Cheng J. Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462 [Abstract] [Full Text] [Related]
10. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Ma JJ, Chen BL, Xin XY. Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744 [Abstract] [Full Text] [Related]
11. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Ma S, Tan W, Du B, Liu W, Li W, Che D, Zhang G. Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490 [Abstract] [Full Text] [Related]
12. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Jiang Y, Jiang J, Jia H, Qiao Z, Zhang J. Cell Physiol Biochem; 2018 Apr; 51(1):129-141. PubMed ID: 30439707 [Abstract] [Full Text] [Related]
14. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X, Zhang RT. BMC Cancer; 2017 Dec 14; 17(1):851. PubMed ID: 29241458 [Abstract] [Full Text] [Related]
15. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells. Hui C, Lan Z, Yue-li L, Li-lin H, Li-lin H. Reprod Sci; 2015 Dec 14; 22(12):1618-26. PubMed ID: 26079730 [Abstract] [Full Text] [Related]
16. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies]. Chen J, Wang Q, Zhang W, Li L. Zhonghua Fu Chan Ke Za Zhi; 2016 Feb 14; 51(2):126-34. PubMed ID: 26917482 [Abstract] [Full Text] [Related]
17. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, Han P, Li Y, Liu M, Zhang Z, Li P. Cell Death Dis; 2018 Oct 30; 9(11):1103. PubMed ID: 30375398 [Abstract] [Full Text] [Related]
20. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X. Oncogene; 2014 Jan 16; 33(3):378-86. PubMed ID: 23318422 [Abstract] [Full Text] [Related] Page: [Next] [New Search]